Toll Free: 1-888-928-9744

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 98 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016', provides an overview of the Neuromyelitis Optica (Devic's Syndrome) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome)
- The report reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Neuromyelitis Optica (Devic's Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Neuromyelitis Optica (Devic's Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Neuromyelitis Optica (Devic's Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Neuromyelitis Optica (Devic's Syndrome) Overview 9 Therapeutics Development 10 Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Overview 10 Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis 11 Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Development by Companies 12 Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Investigation by Universities/Institutes 14 Neuromyelitis Optica (Devic's Syndrome) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Neuromyelitis Optica (Devic's Syndrome) - Products under Development by Companies 18 Neuromyelitis Optica (Devic's Syndrome) - Products under Investigation by Universities/Institutes 19 Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development 20 Acorda Therapeutics, Inc. 20 Alexion Pharmaceuticals Inc 21 Biogen Inc 22 Bionure Farma, S.L. 23 Chugai Pharmaceutical Co., Ltd. 24 Clene Nanomedicine, Inc. 25 HanAll Biopharma Co., Ltd. 26 Karus Therapeutics Limited 27 LFB S.A. 28 Marathon Pharmaceuticals, LLC 29 MedImmune, LLC 30 Opexa Therapeutics, Inc. 31 Shire Plc 32 Takeda Pharmaceutical Company Limited 33 Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment 34 Assessment by Monotherapy Products 34 Assessment by Target 35 Assessment by Mechanism of Action 37 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 ANV-201 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 BN-201 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 C1 esterase inhibitor (human) - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 cladribine - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 CNMAU-8 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 D-15107 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 dalfampridine ER - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 eculizumab - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 HL-161 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 immune globulin (human) - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 inebilizumab - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 KA-1463 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 OPX-212 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 rituximab - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 SA-237 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Small Molecule for Neuromyelitis Optica - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 ublituximab - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects 88 Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones 89 Featured News & Press Releases 89 Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder 89 Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab) 89 Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program 90 Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol 91 May 08, 2015: Initiation Of Phase I Clinical Program 91 Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting 91 Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned 92 Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica 92 Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program 92 Aug 27, 2014: Clene Files Investigational New Drug Application With FDA 93 Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 93 Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA 94 Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles 95 Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion 95 Jul 16, 2013: Alexion's Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica 96 Appendix 97 Methodology 97 Coverage 97 Secondary Research 97 Primary Research 97 Expert Panel Validation 97 Contact Us 97 Disclaimer 98
List of Tables
Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2016 10 Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Acorda Therapeutics, Inc., H2 2016 20 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 21 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Biogen Inc, H2 2016 22 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma, S.L., H2 2016 23 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 24 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Clene Nanomedicine, Inc., H2 2016 25 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 26 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Karus Therapeutics Limited, H2 2016 27 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by LFB S.A., H2 2016 28 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016 29 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune, LLC, H2 2016 30 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics, Inc., H2 2016 31 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H2 2016 32 Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 33 Assessment by Monotherapy Products, H2 2016 34 Number of Products by Stage and Target, H2 2016 36 Number of Products by Stage and Mechanism of Action, H2 2016 38 Number of Products by Stage and Route of Administration, H2 2016 40 Number of Products by Stage and Molecule Type, H2 2016 42 Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H2 2016 88



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify